Integrating metabolic rehabilitation with incretin-based therapies promotes sustainable fat loss and preserves lean mass

While obesity is a chronic condition with significant cardiometabolic morbidity, incretin-based anti-obesity therapies, including GLP-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 RAs (e.g., tirzepatide), have revolutionized its management. These agents achieve clinically meaningful weight loss and improve glycemic and cardiometabolic risk profiles. However, a notable limitation is the reduction in lean tissue observed in many studies, and the long-term clinical significance of these body-composition changes remains undefined. Metabolic rehabilitation, encompassing structured exercise, nutrition optimization, and behavioral support, independently offers benefits in preserving lean mass, improving insulin sensitivity, and enhancing cardiopulmonary fitness, addressing gaps left by pharmacologic appetite suppression alone.

This narrative review synthesized current evidence on the physiological effects of incretin-based obesity pharmacotherapy and metabolic rehabilitation. The authors explored the mechanistic rationale for their combined use, reviewing available clinical data to identify synergistic benefits. They also proposed a practical framework for integrated obesity care, aiming to optimize patient outcomes. The review highlighted key knowledge gaps and future research priorities, providing a comprehensive overview of a multimodal strategy for sustainable weight loss and improved body composition.

The review found that combining incretin-based therapy with metabolic rehabilitation provides additive and complementary benefits, promoting sustainable fat loss while mitigating adverse metabolic adaptations. Incretin therapies induce significant weight loss, but metabolic rehabilitation specifically addresses skeletal muscle quality, bone health, and functional capacity, domains not directly targeted by pharmacologic appetite suppression. This integrated approach is hypothesized to preserve lean mass more effectively than pharmacotherapy alone, improving overall body composition. The synthesis suggests that while incretin-based therapies are highly effective for weight reduction, their combination with structured exercise and nutritional support can lead to more favorable long-term outcomes, particularly regarding muscle and bone health. The review emphasized that reductions in DXA-derived lean mass with incretin therapy should not be assumed to represent impaired muscle quality, strength, or function, as no published clinical trial has demonstrated such impairment. Instead, metabolic rehabilitation can actively enhance these aspects.

Emerging evidence suggests that combining incretin-based therapy with metabolic rehabilitation may provide additive and complementary benefits, promote sustainable fat loss, while mitigating adverse metabolic adaptations.